Femprox

Femprox®

Alprostadil A topical hormone analogue in clinical trials for treating ♀ sexual dysfunction. See Sexual dysfunction. .
References in periodicals archive ?
Net proceeds are expected to be used by the company for general corporate purposes, working capital, capital expenditures, research and development expenditures, clinical trial expenditures and additional approval efforts related to Vitaros and Femprox.
Apricus now plans to zero in on its "high value" operations, including its Vitaros drug for the treatment of erectile dysfunction and Femprox for female sexual arousal disorder.
M2 PHARMA-May 8, 2012-Apricus Biosciences Inc wins Health Canada's approval for Pre-NDS meeting for Femprox for FSAD(C)2012 M2 COMMUNICATIONS
Femprox Cream: A proprietary product currently in Phase 2 clinical development for female sexual dysfunction.
has announced that CJ Corporation, one of the top five pharmaceuticals companies in South Korea, has licensed Femprox for Korea.
As a response to their plight, the drug company NexMed developed Femprox, a lotion which gives "warm and pleasant sensations" when rubbed onto the genital area.
Many of the drugs currently in development - VasoFem, Alista, Femprox - act in the same way as Viagra by engorging the tissues of the genital area.
an emerging international pharmaceutical and medical device company, is developing 1) Alprox-TD and Femprox, topically-applied treatments for male and female sexual dysfunction; and 2) Viratrol, a non-invasive, hand-held device for treating oral and genital herpes.
has reported the Phase I clinical trial results on its Femprox topical treatment for female sexual dysfunction ("FSD"), conducted at the Robert Wood Johnson Medical School ("RWJMS") in New Brunswick, New Jersey.
Apricus Bio") (Nasdaq: APRI) backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT([R]) drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Japanese Patent Office has issued a Decision to Grant a Patent for the Company's application on Femprox entitled, "Compositions and Methods for Amelioration of Human Female Sexual Dysfunction.
M2 EQUITYBITES-October 19, 2010-Apricus Biosciences Inc receives first patent allowance for Femprox in Japan(C)2010 M2 COMMUNICATIONS http://www.
NexMed has several alprostadil-based treatments under development, including Vitaros for erectile dysfunction, Femprox for female sexual arousal disorder and RayVa for Raynaud's syndrome.